Northern Trust’s X4 Pharmaceuticals XFOR Stock Holding History

Northern Trust’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$736K	Hold	178,235	–	–	﹤0.01%	3465
2025 Q4	$713K	Buy	+178,235	New	+$648K	﹤0.01%	3525
2025 Q2	–	Sell	-41,794	Closed	-$296K	–	4504
2025 Q1	$296K	Sell	41,794 -3,457	-8%	-$47.6K	﹤0.01%	3796
2024 Q4	$996K	Buy	45,251 +1,264	+3%	+$20.1K	﹤0.01%	3395
2024 Q3	$883K	Buy	43,987 +8,787	+25%	+$183K	﹤0.01%	3402
2024 Q2	$612K	Buy	35,200 +50	+0.1%	+$1.64K	﹤0.01%	3431
2024 Q1	$1.47M	Sell	35,150 -283	-0.8%	-$7.87K	﹤0.01%	3131
2023 Q4	$891K	Sell	35,433 -157	-0.4%	-$3.82K	﹤0.01%	3351
2023 Q3	$1.16M	Buy	35,590 +527	+2%	+$23K	﹤0.01%	3238
2023 Q2	$2.04M	Buy	35,063 +27,581	+369%	+$1.42M	﹤0.01%	2995
2023 Q1	$195K	Buy	7,482 +2,592	+53%	+$76K	﹤0.01%	3866
2022 Q4	$146K	Buy	4,890 +2,050	+72%	+$97.1K	﹤0.01%	3985
2022 Q3	$146K	Buy	2,840 +981	+53%	+$33.9K	﹤0.01%	3993
2022 Q2	$54K	Buy	1,859 +11	+0.6%	+$418	﹤0.01%	4383
2022 Q1	$97K	Sell	1,848 -402	-18%	-$23.1K	﹤0.01%	4348
2021 Q4	$155K	Sell	2,250 -12	-0.5%	-$1.52K	﹤0.01%	4289
2021 Q3	$359K	Sell	2,262 -23	-1%	-$3.78K	﹤0.01%	3895
2021 Q2	$446K	Sell	2,285 -3,728	-62%	-$937K	﹤0.01%	3756
2021 Q1	$1.55M	Sell	6,013 -920	-13%	-$242K	﹤0.01%	3379
2020 Q4	$1.34M	Sell	6,933 -768	-10%	-$151K	﹤0.01%	3392
2020 Q3	$1.56M	Sell	7,701 -331	-4%	-$79.3K	﹤0.01%	3173
2020 Q2	$2.25M	Buy	8,032 +1,913	+31%	+$524K	﹤0.01%	2980
2020 Q1	$1.84M	Buy	6,119 +1,470	+32%	+$417K	﹤0.01%	2902
2019 Q4	$1.49M	Buy	4,649 +843	+22%	+$302K	﹤0.01%	3258
2019 Q3	$1.45M	Buy	3,806 +2,937	+338%	+$1.16M	﹤0.01%	3261
2019 Q2	$392K	Buy	+869	New	+$442K	﹤0.01%	3622
2019 Q1	–	Sell	-303	Closed	-$127K	–	4263
2018 Q4	$127K	Buy	303 +19	+7%	+$7.25K	﹤0.01%	3875
2018 Q3	$83K	Buy	284 +5	+2%	+$2.12K	﹤0.01%	4062
2018 Q2	$182K	Buy	279 +101	+57%	+$331K	﹤0.01%	3887
2018 Q1	$735K	Buy	+178	New	+$518K	﹤0.01%	3467

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Northern Trust's XFOR Position: Q1 2026 in Review

Northern Trust held its X4 Pharmaceuticals (XFOR) position steady in Q1 2026 at 178,235 shares worth $736K. The position accounts for ﹤0.01% of the portfolio, ranked #3465.

Northern Trust first reported a position in XFOR in Q1 2018 and has held it in 30 quarters since. The position peaked at $2.25M in Q2 2020. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Northern Trust held 178,235 shares of X4 Pharmaceuticals worth $736K as of Q1 2026.
Northern Trust left its X4 Pharmaceuticals share count unchanged in Q1 2026.
X4 Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3465 holding.
Northern Trust first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
Northern Trust's X4 Pharmaceuticals position peaked at $2.25M in Q2 2020.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.